Comparison of CBD Oil and Water-Soluble CBD in Canine Patients with Osteoarthritis
Osteoarthritis is the most common form of arthritis in dogs. It is a chronic joint disease and can occur due to genetics and secondarily to other orthopedic diseases. It is typically treated with weight maintenance, modifying activity, joint supplements, and pain control with NSAIDs (“Osteoarthritis in Dogs”, n.d.). Cannabis sativa is the plant that marijuana and hemp come from. (Kogan et al., 2016). CBD does not produce euphoria or intoxication like the main psychoactive cannabinoid, tetrahydrocannabinol (THC). THC and CBD react on different receptors and more evidence shows that CBD acts on different types of brain signaling and that that may contribute to its therapeutic effects (“The Biology and Potential Therapeutic Effects of Cannabidiol”, 2015).
There are potentially anti-inflammatory properties in CBD. There is limited evidence for treating diseases in animals with CBD but there have been pilot studies with osteoarthritis pain that provided promising results (Deabold et al., 2019).
Water-Soluble CBD is made with a nanotechnology that allows CBD to be absorbed in water rather than an oil. In the research done thus far, it shows that the body absorbs Water-Soluble CBD easier than CBD oil because the nanoparticles can enter the bloodstream and cells quicker (Clark, 2021).
The main goal in comparing CBD oil and Water-Soluble CBD is to see if the potential increase in bioavailability in Water-Soluble CBD seen thus far in humans translates to canines and how this will potentially impact the amount of arthritis pain relief that could occur.
Clinical trial patients would be placed into one of three groups: a CBD oil group, a Water-Soluble group, and a placebo group. Subjective data will be collected through owner surveys that would be filled out in the beginning, 4 weeks in, and 8 weeks into the trial. These surveys would be sued to determine quality of life and reduction of pain that could indicate that the CBD product is helping with osteoarthritis pain.
Objective data will come from the Tekscan 2-Tile Standard Resolution Strideway System (force plate). This will perform gait analysis to determine pressure placed on each paw as they walk on the force plate. This data will be used to determine if participants had any variation in gait throughout the study. This will also occur at the beginning, 4 weeks in, and 8 weeks into the clinical trial. Treatment will end completely at the end of the 8 weeks.
We will also be taking bloodwork at the beginning, 4 weeks in, and 8 weeks into the clinical trial to evaluate any potential side effects that could be caused by the treatments provided in the study.
Hutson School of Agriculture
Bachelor of Science: Agriculture
Hutson School of Agriculture
Beginning date of project
End date of project
Sims, Sadie, "Comparison of CBD Oil and Water-Soluble CBD in Canine Patients with Osteoarthritis" (2022). ORCA Travel & Research Grants. 111.